Rumors continue to swirl that Amgen is in process of making an offer to buy Actelion. Analysts state that such a deal could be for as much as $9.8 B which would be the second largest European biotech deal ever behind Merck's acquisition of Serono for $10.3 B euros in 2007.
PharmaGossip: Actelion, Eyed by Amgen, May Fetch $9.8 Billion in Takeover, Analysts Say - Bloomberg.
Amgen would acquire Actelion's drug Tracleer, for treatment of pulmonary arterial hypertension (PAH) which has patent life through 2015. Actelion has two additional PAH drugs in its current pipeline as replacement therapies. See Bloomberg for more.
Posted by Bruce Lehr November 18th 2010.
More from Fierce Biotech on how analysts are valuating a company like Actelion in setting the expected deal price
http://www.fiercebiotech.com/story/how-do-you-price-biotech-company-actelion/2010-11-18?utm_medium=rss&utm_source=rss
Posted by: bigredbruce | 11/18/2010 at 08:32 AM